Mesoblast Limited stock analysis
Mesoblast Limited (LWB) Stock Price & Analysis
LWB Stock Chart & Stats
- Day’s Range
- EUR 1.13 - EUR 1.13
- 52-Week Range
- EUR 1.06 - EUR 1.71
- Previous Close
- EUR 1.17
- Volume
- N/A
- Average Volume (3M)
- 243
- Market Cap
- EUR 1.50B
- Enterprise Value
- EUR 3.52B
- Total Cash (Recent Filing)
- EUR 47.39M
- Total Debt (Recent Filing)
- EUR 127.33M
- Price to Earnings (P/E)
- ―
- Beta
- 0.98
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- -0.02
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Ryoncil Commercial Traction
Ryoncil has established a meaningful commercial base, supported by rapid treatment-center onboarding and broad payer access. Management’s FY2026 revenue guidance indicates further near-term growth, which could improve revenue visibility and enable operating scale as adoption expands.
High Gross Margin
The exceptionally high reported gross margin gives each incremental Ryoncil sale substantial contribution potential after product costs. If commercial investment becomes more efficient as the launch matures, this product economics could support future margin expansion and stronger earnings quality.
Advanced Clinical Pipeline
Mesoblast has multiple advanced programs with defined clinical and regulatory milestones, rather than relying solely on early research. Revascor and rexlemestrocel-L provide potential future indications and product opportunities that could broaden the company’s commercial platform over time.
Bears Say
Persistent Losses And Cash Burn
The company remains dependent on funding while operating cash flow and free cash flow are negative. Continued losses reduce financial flexibility and mean commercial growth must eventually outpace development and operating costs for Mesoblast to become self-sustaining.
Ryoncil Revenue Concentration
Near-term performance is highly dependent on one recently launched product, making revenue growth sensitive to Ryoncil’s adoption and execution. Until other programs generate commercial revenue, this concentration limits diversification and leaves the growth profile exposed to product-specific outcomes.
Elevated Development And Launch Spending
Substantially higher R&D and commercial spending is funding pipeline advancement and the Ryoncil launch, but it also prolongs losses and cash consumption. Mesoblast must convert these investments into durable product growth and approvals before they can translate into sustainable profitability.
LWB FAQ
What was Mesoblast Limited’s price range in the past 12 months?
What is Mesoblast Limited’s market cap?
When is Mesoblast Limited’s upcoming earnings report date?
How were Mesoblast Limited’s earnings last quarter?
Is Mesoblast Limited overvalued?
Does Mesoblast Limited pay dividends?
What is Mesoblast Limited’s EPS estimate?
How many shares outstanding does Mesoblast Limited have?
What happened to Mesoblast Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Mesoblast Limited?
What is the TipRanks Smart Score and how is it calculated?
Mesoblast Limited Stock Smart Score
Company Description
Mesoblast Limited
Mesoblast Limited, an Australian enterprise established in Melbourne in 2004, is dedicated to developing innovative regenerative medicine products. The company's global reach extends to the United States, Singapore, the United Kingdom, and Switzerland. Its therapeutic endeavors encompass a wide array of medical conditions, including cardiovascular diseases, spinal and orthopedic ailments, oncology, hematology, and immune-mediated and inflammatory disorders. Mesoblast's distinctive regenerative medicine platform is founded on the therapeutic potential of specialized mesenchymal lineage cells. A prominent candidate, Remestemcel-L, is currently in late-stage (Phase III) clinical trials for various systemic inflammatory conditions, such as steroid-refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic-refractory inflammatory bowel disease. Additionally, Remestemcel-L is undergoing Phase III evaluation for chronic heart failure and chronic low back pain linked to degenerative disc disease. The company's pipeline also features MPC-300-IV, under development for biologic-refractory rheumatoid arthritis and diabetic nephropathy, and MPC-25-IC, aimed at treating or preventing acute myocardial infarction. Mesoblast has forged key strategic partnerships, including one with Tasly Pharmaceutical Group for the commercialization of MPC-150-IM (for heart failure) and MPC-25-IC (for heart attacks) in China. It also collaborates with JCR Pharmaceuticals Co. Ltd. on wound healing therapies for epidermolysis bullosa patients, and with Grünenthal to advance and market a cell therapy for chronic low back pain.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Silviu Itescu
- Employees
- 108
- Website
- www.mesoblast.com
- Address
- 55 Collins Street, Melbourne, VIC, 3000, AU
Mesoblast Limited (LWB) Earnings & Revenues
LWB Earnings Call
Earnings Call SentimentPositive
The call communicated strong commercial momentum from the Ryoncil launch (USD 49M H1 revenue), industry-leading gross margins (93%), broad payer coverage, rapid center onboarding and multiple near-term regulatory and clinical milestones (Revascor BLA next quarter; back pain enrollment completion and 2027 BLA). The company also strengthened its balance sheet with USD 130M cash and a USD 125M credit facility. Offsetting risks include a sharp increase in R&D and SG&A spending, reliance on Ryoncil for most revenues, ongoing manufacturing/CMC items ahead of filings, and near-term cash usage (USD 30.3M H1) with a tranche deadline in June 2026. Overall, the positive operational, clinical and financial developments materially outweigh the execution and expense risks.
View all DE:LWB earnings summariesLWB Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 2 | 15 |
| Technical Analysis | 5 | 2 | 3 |
| Moving Averages | 0 | 0 | 12 |












